Publications
Found 1 results
Filters: Author is D. Gunay [Clear All Filters]
“11β-hydroxysteroid dehydrogenase type 1 gene expression is increased in ascending aorta tissue of metabolic syndrome patients with coronary artery disease”, vol. 11, pp. 3122-3132, 2012.
,
Alberti L, Girola A, Gilardini L, Conti A, et al. (2007). Type 2 diabetes and metabolic syndrome are associated with increased expression of 11β-hydroxysteroid dehydrogenase 1 in obese subjects. Int. J. Obes. 31: 1826-1831.
http://dx.doi.org/10.1038/sj.ijo.0803677
PMid:17593901
Baker AR, Silva NF, Quinn DW, Harte AL, et al. (2006). Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular disease. Cardiovasc. Diabetol. 5: 1.
http://dx.doi.org/10.1186/1475-2840-5-1
PMid:16412224 PMCid:1352345
Balkau B, Vernay M, Mhamdi L, Novak M, et al. (2003). The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome. The French D.E.S.I.R. study. Diabetes Metab. 29: 526-532.
http://dx.doi.org/10.1016/S1262-3636(07)70067-8
Boullu-Ciocca S, Dutour A, Guillaume V, Achard V, et al. (2005). Postnatal diet-induced obesity in rats upregulates systemic and adipose tissue glucocorticoid metabolism during development and in adulthood: its relationship with the metabolic syndrome. Diabetes 54: 197-203.
http://dx.doi.org/10.2337/diabetes.54.1.197
PMid:15616029
Bujalska IJ, Kumar S and Stewart PM (1997). Does central obesity reflect "Cushing's disease of the omentum?" Lancet 349: 1210-1213.
http://dx.doi.org/10.1016/S0140-6736(96)11222-8
Bujalska IJ, Kumar S, Hewison M and Stewart PM (1999). Differentiation of adipose stromal cells: the roles of glucocorticoids and 11β-hydroxysteroid dehydrogenase. Endocrinology 140: 3188-3196.
http://dx.doi.org/10.1210/en.140.7.3188
PMid:10385414
Bujalska IJ, Walker EA, Hewison M and Stewart PM (2002a). A switch in dehydrogenase to reductase activity of 11β-hydroxysteroid dehydrogenase type 1 upon differentiation of human omental adipose stromal cells. J. Clin. Endocrinol. Metab. 87: 1205-1210.
http://dx.doi.org/10.1210/jc.87.3.1205
PMid:11889189
Bujalska IJ, Walker EA, Tomlinson JW, Hewison M, et al. (2002b). 11β-hydroxysteroid dehydrogenase type 1 in differentiating omental human preadipocytes: from de-activation to generation of cortisol. Endocr. Res. 28: 449-461.
http://dx.doi.org/10.1081/ERC-120016822
PMid:12530648
Bujalska IJ, Durrani OM, Abbott J, Onyimba CU, et al. (2007). Characterisation of 11β-hydroxysteroid dehydrogenase 1 in human orbital adipose tissue: a comparison with subcutaneous and omental fat. J. Endocrinol. 192: 279-288.
http://dx.doi.org/10.1677/JOE-06-0042
PMid:17283228 PMCid:1994563
Dallman MF, Pecoraro N, Akana SF, La Fleur SE, et al. (2003). Chronic stress and obesity: a new view of "comfort food". Proc. Natl. Acad. Sci. U. S. A. 100: 11696-11701.
http://dx.doi.org/10.1073/pnas.1934666100
PMid:12975524 PMCid:208820
Desbriere R, Vuaroqueaux V, Achard V, Boullu-Ciocca S, et al. (2006). 11β-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients. Obesity (Silver Spring) 14: 794-798.
http://dx.doi.org/10.1038/oby.2006.92
PMid:16855188
Hermanowski-Vosatka A, Gerhold D, Mundt SS, Loving VA, et al. (2000). PPARα agonists reduce 11β-hydroxysteroid dehydrogenase type 1 in the liver. Biochem. Biophys. Res. Commun. 279: 330-336.
http://dx.doi.org/10.1006/bbrc.2000.3966
PMid:11118287
Hermanowski-Vosatka A, Balkovec JM, Cheng K, Chen HY, et al. (2005). 11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J. Exp. Med. 202: 517-527.
http://dx.doi.org/10.1084/jem.20050119
PMid:16103409 PMCid:2212859
Hotamisligil GS and Spiegelman BM (1994). Tumor necrosis factor α: a key component of the obesity-diabetes link. Diabetes 43: 1271-1278.
http://dx.doi.org/10.2337/diabetes.43.11.1271
PMid:7926300
Iacobellis G, Ribaudo MC, Assael F, Vecci E, et al. (2003). Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: a new indicator of cardiovascular risk. J. Clin. Endocrinol. Metab. 88: 5163-5168.
http://dx.doi.org/10.1210/jc.2003-030698
PMid:14602744
Iacobellis G, Corradi D and Sharma AM (2005a). Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart. Nat. Clin. Pract. Cardiovasc. Med. 2: 536-543.
http://dx.doi.org/10.1038/ncpcardio0319
PMid:16186852
Iacobellis G, Pistilli D, Gucciardo M, Leonetti F, et al. (2005b). Adiponectin expression in human epicardial adipose tissue in vivo is lower in patients with coronary artery disease. Cytokine 29: 251-255.
PMid:15749025
IDF (International Diabetes Federation) (2005). The IDF Concensus Worldwide Definition of the Metabolic Syndrome. Available at [http://www.idf.org/webdata/docs/metac_syndrome_def.pdf]. Accessed October 19, 2005.
Kolak M, Yki-Jarvinen H, Kannisto K, Tiikkainen M, et al. (2007). Effects of chronic rosiglitazone therapy on gene expression in human adipose tissue in vivo in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 92: 720-724.
http://dx.doi.org/10.1210/jc.2006-1465
PMid:17148569
Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, et al. (1997). 11β-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc. Natl. Acad. Sci. U. S. A. 94: 14924-14929.
http://dx.doi.org/10.1073/pnas.94.26.14924
PMid:9405715 PMCid:25139
Lindsay RS, Wake DJ, Nair S, Bunt J, et al. (2003). Subcutaneous adipose 11β-hydroxysteroid dehydrogenase type 1 activity and messenger ribonucleic acid levels are associated with adiposity and insulinemia in Pima Indians and Caucasians. J. Clin. Endocrinol. Metab. 88: 2738-2744.
http://dx.doi.org/10.1210/jc.2002-030017
PMid:12788882
Liu J, Wang L, Zhang A, Di W, et al. (2011). Adipose tissue-targeted 11β-hydroxysteroid dehydrogenase type 1 inhibitor protects against diet-induced obesity. Endocr. J. 58: 199-209.
http://dx.doi.org/10.1507/endocrj.K10E-318
PMid:21325744
Liu Y, Sun WL, Sun Y, Hu G, et al. (2006). Role of 11-β-hydroxysteroid dehydrogenase type 1 in differentiation of 3T3- L1 cells and in rats with diet-induced obesity. Acta Pharmacol. Sin. 27: 588-596.
http://dx.doi.org/10.1111/j.1745-7254.2006.00316.x
PMid:16626514
Masuzaki H and Flier JS (2003). Tissue-specific glucocorticoid reactivating enzyme, 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) - a promising drug target for the treatment of metabolic syndrome. Curr. Drug Targets Immune. Endocr. Metabol. Disord. 3: 255-262.
http://dx.doi.org/10.2174/1568008033340135
PMid:14683456
Masuzaki H, Paterson J, Shinyama H, Morton NM, et al. (2001). A transgenic model of visceral obesity and the metabolic syndrome. Science 294: 2166-2170.
http://dx.doi.org/10.1126/science.1066285
PMid:11739957
Morton NM, Ramage L and Seckl JR (2004). Down-regulation of adipose 11β-hydroxysteroid dehydrogenase type 1 by high-fat feeding in mice: a potential adaptive mechanism counteracting metabolic disease. Endocrinology 145: 2707-2712.
http://dx.doi.org/10.1210/en.2003-1674
PMid:15044372
Nakano S, Inada Y, Masuzaki H, Tanaka T, et al. (2007). Bezafibrate regulates the expression and enzyme activity of 11β-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes. Am. J. Physiol. Endocrinol. Metab. 292: E1213-E1222.
http://dx.doi.org/10.1152/ajpendo.00340.2006
PMid:17190905
Onat A (2004). Lipids, lipoproteins and apolipoproteins among turks, and impact on coronary heart disease. Anadolu Kardiyol. Derg. 4: 236-245.
PMid:15355827
Paulsen SK, Pedersen SB, Fisker S and Richelsen B (2007). 11β-HSD type 1 expression in human adipose tissue: impact of gender, obesity, and fat localization. Obesity (Silver Spring) 15: 1954-1960.
http://dx.doi.org/10.1038/oby.2007.233
PMid:17712112
Reape TJ and Groot PH (1999). Chemokines and atherosclerosis. Atherosclerosis 147: 213-225.
http://dx.doi.org/10.1016/S0021-9150(99)00346-9
Rebuffe-Scrive M, Bronnegard M, Nilsson A, Eldh J, et al. (1990). Steroid hormone receptors in human adipose tissues. J. Clin. Endocrinol. Metab. 71: 1215-1219.
http://dx.doi.org/10.1210/jcem-71-5-1215
PMid:2229280
Sheppard KE and Autelitano DJ (2002). 11β-hydroxysteroid dehydrogenase 1 transforms 11-dehydrocorticosterone into transcriptionally active glucocorticoid in neonatal rat heart. Endocrinology 143: 198-204.
http://dx.doi.org/10.1210/en.143.1.198
PMid:11751610
Silaghi A, Achard V, Paulmyer-Lacroix O, Scridon T, et al. (2007). Expression of adrenomedullin in human epicardial adipose tissue: role of coronary status. Am. J. Physiol. Endocrinol. Metab. 293: E1443-E1450.
http://dx.doi.org/10.1152/ajpendo.00273.2007
PMid:17878224
Staab CA and Maser E (2010). 11β-Hydroxysteroid dehydrogenase type 1 is an important regulator at the interface of obesity and inflammation. J. Steroid Biochem. Mol. Biol. 119: 56-72.
http://dx.doi.org/10.1016/j.jsbmb.2009.12.013
PMid:20045052
Stewart PM (2003). Tissue-specific Cushing's syndrome, 11β-hydroxysteroid dehydrogenases and the redefinition of corticosteroid hormone action. Eur. J. Endocrinol. 149: 163-168.
http://dx.doi.org/10.1530/eje.0.1490163
PMid:12943516
Tomlinson JW, Walker EA, Bujalska IJ, Draper N, et al. (2004). 11β-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr. Rev. 25: 831-866.
http://dx.doi.org/10.1210/er.2003-0031
PMid:15466942
Trevisan M, Liu J, Bahsas FB and Menotti A (1998). Syndrome X and mortality: a population-based study. Risk Factor and Life Expectancy Research Group. Am. J. Epidemiol. 148: 958-966.
http://dx.doi.org/10.1093/oxfordjournals.aje.a009572
PMid:9829867
Weber C, Schober A and Zernecke A (2004). Chemokines: key regulators of mononuclear cell recruitment in atherosclerotic vascular disease. Arterioscler. Thromb. Vasc. Biol. 24: 1997-2008.
http://dx.doi.org/10.1161/01.ATV.0000142812.03840.6f
PMid:15319268
Wilson PW, Kannel WB, Silbershatz H and D'Agostino RB (1999). Clustering of metabolic factors and coronary heart disease. Arch. Intern. Med. 159: 1104-1109.
http://dx.doi.org/10.1001/archinte.159.10.1104
PMid:10335688
Xu H, Barnes GT, Yang Q, Tan G, et al. (2003). Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 112: 1821-1830.
PMid:14679177 PMCid:296998